Vertex Pain Deal History & Licensing Activity
Vertex Pain is a large biotech headquartered in US. Over the past three years, Vertex Pain has been involved in 2 licensing and acquisition transactions, with a primary focus on Gene Therapy (3 deals).
Deals (12mo)
1
Active Trials
8
Top Modality
Gene Therapy
Focus Area
Hematology
Vertex Pain Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Vertex Pain in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| exagamglogene autotemcel | Vertex | Gene Therapy | Approved | collaboration | Mar 2026 |
Vertex Pain Pipeline Focus
Therapeutic areas and modalities where Vertex Pain is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Vertex Pain Strategic Signals
Key indicators of Vertex Pain's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Vertex Pain's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Hematology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Hematology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for hematology
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Vertex Pain Licensing & Deal Activity
Vertex Pain is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Vertex Pain ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Vertex Pain include Hematology (2 deals and trials), and Rare Disease (1 deal and trial). In terms of modality, Vertex Pain has shown particular interest in gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Vertex Pain and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Vertex Pain's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.